Local Control and Regulation of Retinal Autoimmunity
视网膜自身免疫的局部控制和调节
基本信息
- 批准号:10339488
- 负责人:
- 金额:$ 38.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAntigen PresentationAntigen TargetingAntigen-Presenting CellsAntigensArrestinsAutoantigensAutoimmuneAutoimmunityBlindnessCD4 Positive T LymphocytesCell CommunicationCellsChronicComplexDendritic CellsDiseaseEquilibriumEyeEye diseasesGenerationsGraves&apos DiseaseHomeostasisITGAX geneImmuneImmune ToleranceImmune responseImmunocompetenceInflammatoryInjuryInsulin-Dependent Diabetes MellitusKnowledgeLocal TherapyMHC antigenMediatingMicrogliaModelingMusMyeloid CellsNatureNeuraxisOrganPeptidesPhenotypePlayPopulationProcessProductionPropertyRegulationRegulatory T-LymphocyteRetinaRheumatoid ArthritisRoleSarcoidosisSeveritiesSignal TransductionSystemic Lupus ErythematosusSystemic TherapyT cell anergyT-LymphocyteTestingTherapeuticTherapeutic UsesThymus GlandTissue GraftsTissuesTransgenic MiceVisualVisual impairmentanergyantigen-specific T cellsautoimmune pathogenesiscell typecytokineeffector T cellimmune functionmouse modelpreventresponseside effecttranslational studyuveoretinitis
项目摘要
Project Summary/Abstract
The balance and function of effector T cells, regulatory T cells, and anergic T cells are critical for maintaining
immune homeostasis. Lack of regulatory T cells (Tregs) leads to autoimmunity mediated by self-antigen
specific effector T cells whose targets can include tissues of the eye. Although most Tregs originate in the
thymus, our previous studies suggest that in response to retinal self-antigens, Tregs can be generated locally
in the retina from conventional CD4+ T cells, a process we refer to as "on-demand" Treg generation. T cell
recognition of antigen-MHC-II complexes in the absence of costimulatory signals or in the presence of
inhibitory signals can induce anergy, a state of functional unresponsiveness and non-proliferation in T cells.
Thus, generation of anergic T cells may be another important mechanism for maintaining retinal immune
homeostasis. We have observed a small number of T cells and a population of myeloid cells (microglia), a
subset of which can act as conventional dendritic cells within the retina. Thus, we hypothesize there is a local,
continual generation of retinal self-antigen specific Tregs and anergic T cells within the retina that contributes
to retinal immune homeostasis and that the interaction between T cells, retinal microglia, and possibly non-
myeloid retinal cells determines the nature and fate of retinal T cells. This hypothesis will be explored in three
aims using the R161H mouse model of spontaneous retinal autoimmunity in conjunction with transgenic mice
that allow for the tracking and depletion of dendritic cells, microglia, and Tregs.
Aim 1: This aim will define the role that retinal microglia, particularly the dendritic cell subset, plays in antigen
presentation that leads to autoimmune pathogenesis in the retina.
Aim 2: This aim will define and distinguish the roles that resident retinal microglia versus the non-myeloid
retinal cells play in production of anergic and regulatory T cells within the retina.
Aim 3: This aim will be translational studies using local therapeutic manipulation of retinal microglia or other
antigen presenting cells to limit T cell co-stimulation and promote generation of anergic and regulatory T cells
to limit inflammatory injury to the retina.
项目总结/摘要
效应T细胞、调节T细胞和无能T细胞的平衡和功能对于维持免疫功能至关重要。
免疫稳态缺乏调节性T细胞(Tcells)导致自身抗原介导的自身免疫
特异性效应T细胞,其靶可包括眼组织。虽然大多数的Tibetan起源于
我们以前的研究表明,在对视网膜自身抗原的反应中,TdR可以在局部产生,
在视网膜中从传统的CD 4 + T细胞中产生Treg,我们称之为“按需”Treg生成的过程。T细胞
在不存在共刺激信号或存在共刺激信号的情况下识别抗原-MHC-II复合物,
抑制信号可诱导无反应性,即T细胞中功能性无反应性和不增殖的状态。
因此,无反应性T细胞的产生可能是维持视网膜免疫的另一重要机制
体内平衡我们已经观察到少量的T细胞和髓样细胞(小胶质细胞),
其亚群可以作为视网膜内的常规树突细胞。因此,我们假设有一个本地的,
视网膜内持续产生视网膜自身抗原特异性T细胞和无反应性T细胞,
视网膜免疫稳态之间的相互作用,视网膜小胶质细胞,并可能非-
髓样视网膜细胞决定视网膜T细胞的性质和命运。这一假设将在三个方面进行探讨。
目的利用R161 H小鼠自发性视网膜自身免疫模型结合转基因小鼠,
它允许追踪和消除树突细胞、小胶质细胞和Tcells。
目的1:明确视网膜小胶质细胞,特别是树突状细胞亚群在抗原表达中的作用,
在视网膜中的自身免疫性发病机制。
目的2:该目的将定义和区分视网膜小胶质细胞与非髓样细胞的作用,
视网膜细胞在视网膜内产生无反应性和调节性T细胞中起作用。
目标3:该目标将是使用视网膜小胶质细胞或其他局部治疗操作的转化研究
抗原呈递细胞,以限制T细胞共刺激并促进无反应性和调节性T细胞的产生
以限制视网膜的炎症损伤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Scott W McPherson其他文献
Scott W McPherson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Scott W McPherson', 18)}}的其他基金
Local Control and Regulation of Retinal Autoimmunity
视网膜自身免疫的局部控制和调节
- 批准号:
10551909 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别:














{{item.name}}会员




